Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,260Revenue (TTM) $M518Net Margin (%)12.9Altman Z-Score7.2
Enterprise Value $M2,145EPS (TTM) $1.1Operating Margin %16.5Piotroski F-Score7
P/E(ttm)34.0Beneish M-Score-2.4Pre-tax Margin (%)18.4Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %4.3Quick Ratio2.9Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %9.5Current Ratio3.8Lower Leverage y-yY
Price/Free Cash Flow41.6y-y EBITDA Growth Rate %-0.6ROA % (ttm)7.2Higher Current Ratio y-yY
Dividend Yield %1.0PEG3.6ROE % (ttm)9.4Less Shares Outstanding y-yY
Payout Ratio %34.0Shares Outstanding M63.7ROIC % (ttm)10.4Gross Margin Increase y-yY

Gurus Latest Trades with TR

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

TR is held by these investors:



TR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LEWIS BRENT LANA JANEDirector 2014-07-31Buy15,914$25.3742.1view
LEWIS BRENT LANA JANEDirector 2013-05-07Sell16,320$28.2727.52view
LEWIS BRENT LANA JANEDirector 2012-03-07Buy2,502$20.1379.09view
WEINER LEIGH R10% Owner 2008-01-23Sell65,239$19.3985.92view
WEINER LEIGH R10% Owner 2006-03-29Sell167,990$21.567.67view
Seibert Barre ADirector 2006-01-06Buy692$20.6374.75view
Seibert Barre ADirector 2005-05-09Buy692$21.9564.24view
LEWIS BRENT LANA JANEDirector 2005-03-22Buy3,668$21.2569.65view
EMBER G HOWARDCFO 2005-03-22Buy7,613$21.2269.89view
WEINER LEIGH R10% Owner 2003-09-18Sell49,902$22.1462.83view

Press Releases about TR :

Quarterly/Annual Reports about TR:

News about TR:

Articles On GuruFocus.com
Spruce Point Capital Releases a Strong Sell Forensic Research Opinion on Tootsie Roll Industries (NY Oct 18 2017 
Dividend Kings in Focus: Tootsie Roll Jun 27 2017 
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 a Jun 07 2016 
Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders May 31 2016 
Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 a May 18 2016 
Trillium Reports First Quarter 2016 Financial Results May 13 2016 
Trillium to Provide Update on CD47 Program at the 2016 American Association for Cancer Research Annu Apr 14 2016 
Trillium to Present at the 2016 Annual Needham Health Care Conference Apr 12 2016 
Trillium Announces a $3.4 Million Government Co-Funded Translational Research Program Mar 10 2016 
Trillium Reports 2015 Financial and Operating Results Mar 09 2016 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK